David Sulman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Sulman has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Mathieu Kerneis
ACTION Study Group, Sorbonne Université, Inserm, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, 75013, France
4 shared publicationsJohanne Silvain
ACTION Study Group, Sorbonne Université, Inserm, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, 75013, France
3 shared publicationsLouis Giovachini
ACTION Study Group, Sorbonne Université, Inserm, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, 75013, France
3 shared publicationsNiki Procopi
Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France
3 shared publicationsPierre Charleux
ACTION Study Group, Sorbonne Université, Inserm, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, 75013, France
3 shared publicationsAlain Combes
Sorbonne Université, Institut de Cardiologie, Service de Médecine Intensive-Réanimation Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Carotid Plaque Score: A Useful Tool or Futile Gadget for Risk Assessment? An Update
Conventional cardiovascular risk scores estimate the probability of future events; however, these risk scores do not directly quantify the presence or extent of subclinical atherosclerosis. This narrative review critically evaluates the current evidence on the carotid plaque score (CPS), a semiquantitative ultrasound-based measure of carotid atherosclerotic burden across predefined arterial segments. Population-based cohorts have consistently shown that carotid plaque presence and burden are independently associated with cardiovascular and cerebrovascular events. Studies specifically evaluating CPS have further suggested an incremental prognostic value beyond conventional risk models, particularly for ischemic stroke and major adverse cardiovascular event (MACE). However, CPS does not represent a single standardized metric. Therefore, proposed thresholds, including CPS ≥2 and CPS >3, were derived using different plaque definitions, arterial segments, scoring methods, and study populations and are not directly interchangeable. Meanwhile, CPS is more accessible, non-ionizing, and relatively inexpensive compared with coronary artery calcium (CAC), but it is less extensively validated and less standardized. Nonetheless, available comparative evidence indicates that CAC provides superior discrimination for coronary outcomes. In contrast, carotid plaque assessment may offer complementary information for cerebrovascular risk and in selected individuals with discordant estimated risk or no detectable coronary calcification. No randomized trial has demonstrated that treatment decisions guided by CPS improve clinical outcomes. Accordingly, current guidelines generally position carotid plaque imaging as a selective risk modifier rather than a routine screening or stand-alone treatment-allocation tool. Thus, broader clinical implementation will require standardized acquisition and reporting protocols, external validation across diverse populations, integration with established risk models, and prospective studies evaluating whether CPS-guided preventive strategies improve patient outcomes.
- 23 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Open AccessCarotid Plaque Score: A Useful Tool or Futile Gadget for Risk Assessment? An Update
Conventional cardiovascular risk scores estimate the probability of future events; however, these risk scores do not directly quantify the presence or extent of subclinical atherosclerosis. This narrative review critically evaluates the current evidence on the carotid plaque score (CPS), a semiquantitative ultrasound-based measure of carotid atherosclerotic burden across predefined arterial segments. Population-based cohorts have consistently shown that carotid plaque presence and burden are independently associated with cardiovascular and cerebrovascular events. Studies specifically evaluating CPS have further suggested an incremental prognostic value beyond conventional risk models, particularly for ischemic stroke and major adverse cardiovascular event (MACE). However, CPS does not represent a single standardized metric. Therefore, proposed thresholds, including CPS ≥2 and CPS >3, were derived using different plaque definitions, arterial segments, scoring methods, and study populations and are not directly interchangeable. Meanwhile, CPS is more accessible, non-ionizing, and relatively inexpensive compared with coronary artery calcium (CAC), but it is less extensively validated and less standardized. Nonetheless, available comparative evidence indicates that CAC provides superior discrimination for coronary outcomes. In contrast, carotid plaque assessment may offer complementary information for cerebrovascular risk and in selected individuals with discordant estimated risk or no detectable coronary calcification. No randomized trial has demonstrated that treatment decisions guided by CPS improve clinical outcomes. Accordingly, current guidelines generally position carotid plaque imaging as a selective risk modifier rather than a routine screening or stand-alone treatment-allocation tool. Thus, broader clinical implementation will require standardized acquisition and reporting protocols, external validation across diverse populations, integration with established risk models, and prospective studies evaluating whether CPS-guided preventive strategies improve patient outcomes.
- Open Access
- 6 October 2026
- Published by Elsevier in Archives of Cardiovascular Diseases
Incidence and determinants of non-radial vascular approach for coronary angiography in heart transplant recipients
- 6 October 2026
- Published by Elsevier in Archives of Cardiovascular Diseases
Open AccessIncidence and determinants of non-radial vascular approach for coronary angiography in heart transplant recipients
- 9 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (3) , 316-327
Efficacy and Safety of Intravenous Antiplatelet Therapy in Acute Myocardial Infarction With Cardiogenic Shock
- 9 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (3) , 316-327
Efficacy and Safety of Intravenous Antiplatelet Therapy in Acute Myocardial Infarction With Cardiogenic Shock
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (2) , qyaf112
What role for cardiac imaging in chronic coronary syndromes: review of the literature in light of the latest recommendations
The 2019 ESC guidelines redefined stable coronary artery disease as chronic coronary syndrome (CCS), highlighting the dynamic nature of this disease. This condition is characterized by the gradual accumulation of atherosclerotic plaques in the epicardial coronary arteries. CCS can result in myocardial ischaemia due to supply–demand mismatch, often triggered by physical or emotional stress. The clinical course may be abruptly interrupted by plaque rupture or erosion, leading to acute coronary syndromes. Revolutionary advances in non-invasive imaging have transformed the chronic coronary syndrome diagnosis algorithm and management. Coronary computed tomography angiography provides detailed anatomical insights, identifying high-risk plaques with features like low attenuation and positive remodelling, as evidenced by SCOT-HEART, which reported reduced coronary events (HR: 0.59, P = 0.004). Stress echocardiography may detect ischaemia-induced wall motion abnormalities (sensitivity, 85–95%), while cardiovascular magnetic resonance is paramount in functional assessment, offering 81–86% sensitivity/specificity and detecting microvascular dysfunction via perfusion and late gadolinium enhancement. Nuclear imaging (SPECT/PET) enhances ischaemia detection, with PET’s myocardial flow reserve improving prognostic accuracy (sensitivity 90%, specificity 88%). AI-driven innovations, such as CT-derived fractional flow reserve, automate plaque quantification and may reduce in the future unnecessary invasive angiographies by 19–25% (P = 0.01), while dynamic CT myocardial perfusion integrates anatomical and hemodynamic data, boosting diagnostic accuracy (87%). These advancements enable precise risk stratification and a personalized multimodal imaging approach, based on pre-test likelihood. It also increases the risk of unsustainable costs for society, repeated radiation exposure throughout a patient's life, and raises the question of actual limited benefits from revascularization in low-risk patients.
- 2 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (2) , qyaf112
Open AccessWhat role for cardiac imaging in chronic coronary syndromes: review of the literature in light of the latest recommendations
The 2019 ESC guidelines redefined stable coronary artery disease as chronic coronary syndrome (CCS), highlighting the dynamic nature of this disease. This condition is characterized by the gradual accumulation of atherosclerotic plaques in the epicardial coronary arteries. CCS can result in myocardial ischaemia due to supply–demand mismatch, often triggered by physical or emotional stress. The clinical course may be abruptly interrupted by plaque rupture or erosion, leading to acute coronary syndromes. Revolutionary advances in non-invasive imaging have transformed the chronic coronary syndrome diagnosis algorithm and management. Coronary computed tomography angiography provides detailed anatomical insights, identifying high-risk plaques with features like low attenuation and positive remodelling, as evidenced by SCOT-HEART, which reported reduced coronary events (HR: 0.59, P = 0.004). Stress echocardiography may detect ischaemia-induced wall motion abnormalities (sensitivity, 85–95%), while cardiovascular magnetic resonance is paramount in functional assessment, offering 81–86% sensitivity/specificity and detecting microvascular dysfunction via perfusion and late gadolinium enhancement. Nuclear imaging (SPECT/PET) enhances ischaemia detection, with PET’s myocardial flow reserve improving prognostic accuracy (sensitivity 90%, specificity 88%). AI-driven innovations, such as CT-derived fractional flow reserve, automate plaque quantification and may reduce in the future unnecessary invasive angiographies by 19–25% (P = 0.01), while dynamic CT myocardial perfusion integrates anatomical and hemodynamic data, boosting diagnostic accuracy (87%). These advancements enable precise risk stratification and a personalized multimodal imaging approach, based on pre-test likelihood. It also increases the risk of unsustainable costs for society, repeated radiation exposure throughout a patient's life, and raises the question of actual limited benefits from revascularization in low-risk patients.
- Open Access
- 1 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (6) , 489-499
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
Background and aims: There are currently no data regarding pre-treatment with P2Y12 inhibitors in patients with acute myocardial infarction complicated with cardiogenic shock (AMI-CS). This study investigates the effectiveness and safety of pre-treatment with P2Y12 inhibitors in patients with AMI-CS. Methods and results: Using the ACTION-SHOCK cohort, we included consecutive patients hospitalized between 2012 and 2023 with AMI-CS admitted for coronary angiography within 24 h of admission. Pretreatment was defined by the administration before angiography of an oral loading dose of a P2Y12 inhibitor. We evaluated the association between pretreatment and either major adverse cardiovascular events (MACE) or major bleeding at 30 days after admission, using an inverse probability weighting (IPW) approach. MACE was defined by the composite of all-cause death, ischaemic stroke, myocardial infarction, or stent thrombosis. Major bleeding was defined by Bleeding Academic Research Consortium grade 3, 4, or 5. Among the 421 patients with AMI-CS admitted to the catheterization laboratory within 24 h of admission, 224 (53.2%) patients received pre-treatment with a P2Y12 inhibitor. No association between pre-treatment with P2Y12 inhibitor and MACE at 30 days was found [42.1% vs. 38.8%—IPW hazard ratio (wHR): 1.11, 95% CI: 0.82–1.50]. Pre-treatment was associated with an increased risk of major bleeding (42.2% vs. 32.3%—wHR: 1.48, 95% CI: 1.05–2.08). The effect of pre-treatment on MACE or major bleeding at 30 days is consistent across STEMI/NSTEMI patients. Conclusion: In patients with AMI-CS, pretreatment with a P2Y12 inhibitor oral load was associated with an increased risk of major bleeding without benefit on MACE.
- 1 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (6) , 489-499
Open AccessPre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
Background and aims: There are currently no data regarding pre-treatment with P2Y12 inhibitors in patients with acute myocardial infarction complicated with cardiogenic shock (AMI-CS). This study investigates the effectiveness and safety of pre-treatment with P2Y12 inhibitors in patients with AMI-CS. Methods and results: Using the ACTION-SHOCK cohort, we included consecutive patients hospitalized between 2012 and 2023 with AMI-CS admitted for coronary angiography within 24 h of admission. Pretreatment was defined by the administration before angiography of an oral loading dose of a P2Y12 inhibitor. We evaluated the association between pretreatment and either major adverse cardiovascular events (MACE) or major bleeding at 30 days after admission, using an inverse probability weighting (IPW) approach. MACE was defined by the composite of all-cause death, ischaemic stroke, myocardial infarction, or stent thrombosis. Major bleeding was defined by Bleeding Academic Research Consortium grade 3, 4, or 5. Among the 421 patients with AMI-CS admitted to the catheterization laboratory within 24 h of admission, 224 (53.2%) patients received pre-treatment with a P2Y12 inhibitor. No association between pre-treatment with P2Y12 inhibitor and MACE at 30 days was found [42.1% vs. 38.8%—IPW hazard ratio (wHR): 1.11, 95% CI: 0.82–1.50]. Pre-treatment was associated with an increased risk of major bleeding (42.2% vs. 32.3%—wHR: 1.48, 95% CI: 1.05–2.08). The effect of pre-treatment on MACE or major bleeding at 30 days is consistent across STEMI/NSTEMI patients. Conclusion: In patients with AMI-CS, pretreatment with a P2Y12 inhibitor oral load was associated with an increased risk of major bleeding without benefit on MACE.
Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines
Objective To determine if the changes in the European Society Cardiology/European Atherosclerotic Society (ESC/EAS) guidelines improved the identification for primary prevention therapy in young adults at risk of a premature myocardial infarction. Methods Patients admitted for a first ST-segment elevation myocardial infarction (STEMI) in the ePARIS registry (n=2757) between 2010 and 2018 were classified by age: 65 years old. Using Systematic Coronary Risk Estimation 2, we evaluated whether patients would have been detected and treated with primary prevention statins before their first STEMI based on the 2021 EAS/ESC guidelines versus 2019 and 2016 guidelines. Eligibility for intensive proprotein convertase subtilisin/kexin type 9 (PCSK9i) in secondary prevention was also assessed. Results Following 2021 ESC guidelines, 62.5% of individuals aged 65 years old (19% and 72%), pConclusions The 2021 ESC guidelines allowed a much better detection of young individuals before their first STEMI than prior ESC guidelines. In secondary prevention, most of young individuals did not reach low-density lipoprotein cholesterol levels recommended, but only one quarter would be eligible for PCSK9i.
Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines
Objective To determine if the changes in the European Society Cardiology/European Atherosclerotic Society (ESC/EAS) guidelines improved the identification for primary prevention therapy in young adults at risk of a premature myocardial infarction. Methods Patients admitted for a first ST-segment elevation myocardial infarction (STEMI) in the ePARIS registry (n=2757) between 2010 and 2018 were classified by age: 65 years old. Using Systematic Coronary Risk Estimation 2, we evaluated whether patients would have been detected and treated with primary prevention statins before their first STEMI based on the 2021 EAS/ESC guidelines versus 2019 and 2016 guidelines. Eligibility for intensive proprotein convertase subtilisin/kexin type 9 (PCSK9i) in secondary prevention was also assessed. Results Following 2021 ESC guidelines, 62.5% of individuals aged 65 years old (19% and 72%), pConclusions The 2021 ESC guidelines allowed a much better detection of young individuals before their first STEMI than prior ESC guidelines. In secondary prevention, most of young individuals did not reach low-density lipoprotein cholesterol levels recommended, but only one quarter would be eligible for PCSK9i.
- Open Access
- 3 September 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (9) , ytab329
A giant left ventricular calcified pseudoaneurysm 24 years following acute myocardial infarction: a case report
A 62-year-old male was admitted with pulmonary oedema. He had a previous history of anterior myocardial infarction in 1997 treated with intravenous fibrinolysis complicated by tamponade requiring surgical drainage. He developed left ventricular (LV) dysfunction [left ventricular ejection fraction (LVEF) 25%] and LV pseudoaneurysm. Despite oral anticoagulation with Vitamin K Antagonist (VKA) with International Normalized Ratio (INR) in the therapeutic range, and low-dose aspirin, he suffered three transient ischaemic attacks in 2009, 2010 again, and 2012 and a stroke in 2017. The LVEF was stable throughout the years, with the first documentation of LV thrombus in 2016. He had not previously shown heart failure symptoms and had no symptoms whilst taking bisoprolol and ramipril. However, the patient elected not to take Bisoprolol for 6 months. On admission, blood pressure was 135/76 mmHg, heart rate 130/min, and he required oxygen at 2 L/min with SpO2 at 97%. Physical examination showed crackles in both lung fields without any other signs of congestion. Biology sample was unremarkable and N-terminal prohormone of brain natriuretic peptide was 659 ng/mL. The electrocardiogram (Panel A) revealed Q waves in anterior and anterolateral leads. Chest X-ray (Panel B) showed a large heavily calcified LV pseudoaneurysm. LVEF was less than 10% on echocardiography with only a preserved contractility in the basal segments of the LV. Cardiac computed tomography (CT) (Panels C and D) and magnetic resonance imaging (MRI) (Panels E and F) showed a severely depressed LVEF (8%) with a 90 mm apical LV pseudoaneurysm without sign of rupture filled with a 12 mm lining thrombus. The LV end-diastolic volume dimension was of 233.86 mL/m2 (N = 77.0 mL/m2). The cardiac index was estimated at 1.56 L/min/m2. Clinical condition improved under intravenous diuretics. He was discharged home under sacubitril/valsartan (24/26 mg, b.i.d.) after Ramipril wash-out, furosemide 40 mg, atorvastatin 40 mg, and increased dose of VKA for a target INR of 2.5–3.5 with the withdrawal of aspirin, without switching for direct oral anticoagulants due to unclear benefit compared to VKA in this situation. Surgical correction of LV pseudoaneurysm was not performed due to very high operative risk with few clinical benefits expected. We recommended the implantation of an internal cardiac defibrillator before discharge; however, the patient refused this intervention despite being provided with information regarding the high risk of ventricular arrhythmias, but however accepted the prescription of a LifeVest (Zoll Medical). He was included in the heart transplant program, with a complete pre-transplant assessment scheduled for a week after discharge. This case allows apprehending the natural course of untreated LV pseudoaneurysm: a low risk of rupture after the acute phase, a calcific remodelling, and a high risk of thrombo-embolic events.
- 3 September 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (9) , ytab329
Open AccessA giant left ventricular calcified pseudoaneurysm 24 years following acute myocardial infarction: a case report
A 62-year-old male was admitted with pulmonary oedema. He had a previous history of anterior myocardial infarction in 1997 treated with intravenous fibrinolysis complicated by tamponade requiring surgical drainage. He developed left ventricular (LV) dysfunction [left ventricular ejection fraction (LVEF) 25%] and LV pseudoaneurysm. Despite oral anticoagulation with Vitamin K Antagonist (VKA) with International Normalized Ratio (INR) in the therapeutic range, and low-dose aspirin, he suffered three transient ischaemic attacks in 2009, 2010 again, and 2012 and a stroke in 2017. The LVEF was stable throughout the years, with the first documentation of LV thrombus in 2016. He had not previously shown heart failure symptoms and had no symptoms whilst taking bisoprolol and ramipril. However, the patient elected not to take Bisoprolol for 6 months. On admission, blood pressure was 135/76 mmHg, heart rate 130/min, and he required oxygen at 2 L/min with SpO2 at 97%. Physical examination showed crackles in both lung fields without any other signs of congestion. Biology sample was unremarkable and N-terminal prohormone of brain natriuretic peptide was 659 ng/mL. The electrocardiogram (Panel A) revealed Q waves in anterior and anterolateral leads. Chest X-ray (Panel B) showed a large heavily calcified LV pseudoaneurysm. LVEF was less than 10% on echocardiography with only a preserved contractility in the basal segments of the LV. Cardiac computed tomography (CT) (Panels C and D) and magnetic resonance imaging (MRI) (Panels E and F) showed a severely depressed LVEF (8%) with a 90 mm apical LV pseudoaneurysm without sign of rupture filled with a 12 mm lining thrombus. The LV end-diastolic volume dimension was of 233.86 mL/m2 (N = 77.0 mL/m2). The cardiac index was estimated at 1.56 L/min/m2. Clinical condition improved under intravenous diuretics. He was discharged home under sacubitril/valsartan (24/26 mg, b.i.d.) after Ramipril wash-out, furosemide 40 mg, atorvastatin 40 mg, and increased dose of VKA for a target INR of 2.5–3.5 with the withdrawal of aspirin, without switching for direct oral anticoagulants due to unclear benefit compared to VKA in this situation. Surgical correction of LV pseudoaneurysm was not performed due to very high operative risk with few clinical benefits expected. We recommended the implantation of an internal cardiac defibrillator before discharge; however, the patient refused this intervention despite being provided with information regarding the high risk of ventricular arrhythmias, but however accepted the prescription of a LifeVest (Zoll Medical). He was included in the heart transplant program, with a complete pre-transplant assessment scheduled for a week after discharge. This case allows apprehending the natural course of untreated LV pseudoaneurysm: a low risk of rupture after the acute phase, a calcific remodelling, and a high risk of thrombo-embolic events.